Table 1 Baseline characteristics
From: Effectiveness and relevant factors of 2 % rebamipide ophthalmic suspension treatment in dry eye
Sex | Female | 21 (87.5 %) |
|---|---|---|
Age (yrs) | Mean | 66.2 |
Dry eye-related symptom score | Mean | 14.5 |
Fluorescein ocular surface staining score | Median R/L | 3.0 / 3.0 |
TBUT (sec) | Median R/L | 2.0 / 2.0 |
Schirmer’s test (mm) | Median R/L | 6.0 / 6.0 |
Previous treatment for dry eye | n (%) | |
none | 11 (45.8 %) | |
AT | 3 (12.5 %) | |
SH | 8 (33.3 %) | |
SH + AT | 2 (8.3 %) | |
Primary disease of dry eye | n (%) | |
non-Sjogren group n = 17 | RA | 1 (5.8 %) |
Basedow disease | 1 (5.8 %) | |
any other autoimmune disease | 4 (23.5 %) | |
none | 11 (64.7 %) | |
Sjogren group n = 7 | Prymary | 3 (42.8 %) |
Secondary | 4 (57.1 %) | |